Canntab Therapeutics Limited
CTABF · OTC
5/31/2022 | 5/31/2021 | 5/31/2020 | 5/31/2019 | |
|---|---|---|---|---|
| Market Cap | $9,542 | $34,577 | $29,834 | $18,618 |
| - Cash | $691 | $1,491 | $2,090 | $414 |
| + Debt | $1,840 | $1,566 | $726 | $0 |
| Enterprise Value | $10,691 | $34,652 | $28,470 | $18,204 |
| Revenue | $293 | $0 | $133 | $240 |
| % Growth | – | -100% | -44.4% | – |
| Gross Profit | -$939 | -$263 | $133 | $144 |
| % Margin | -320.1% | – | 100% | 59.8% |
| EBITDA | -$2,488 | -$3,134 | -$2,285 | -$2,421 |
| % Margin | -848% | – | -1,713.8% | -1,008.8% |
| Net Income | -$3,689 | -$4,420 | -$2,607 | -$2,459 |
| % Margin | -1,257.6% | – | -1,955.4% | -1,024.4% |
| EPS Diluted | -0.098 | -0.13 | -0.096 | -0.097 |
| % Growth | 24.8% | -35.4% | 1.2% | – |
| Operating Cash Flow | -$2,846 | -$2,849 | -$1,899 | -$2,333 |
| Capital Expenditures | -$88 | -$345 | -$905 | -$318 |
| Free Cash Flow | -$2,934 | -$3,195 | -$2,805 | -$2,651 |